Charles Schwab Investment Management Inc. Boosts Position in Haleon PLC Sponsored ADR $HLN

Charles Schwab Investment Management Inc. raised its position in Haleon PLC Sponsored ADR (NYSE:HLN) by 28.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 342,213 shares of the company’s stock after buying an additional 76,469 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Haleon were worth $3,521,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bartlett & CO. Wealth Management LLC increased its holdings in shares of Haleon by 135.9% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 2,588 shares of the company’s stock valued at $27,000 after purchasing an additional 1,491 shares during the period. Opal Wealth Advisors LLC acquired a new position in Haleon during the first quarter worth $29,000. Continuum Advisory LLC grew its holdings in Haleon by 152.4% during the first quarter. Continuum Advisory LLC now owns 4,753 shares of the company’s stock worth $49,000 after acquiring an additional 2,870 shares during the period. Alpine Bank Wealth Management acquired a new position in Haleon during the first quarter worth $56,000. Finally, Cullen Frost Bankers Inc. grew its holdings in Haleon by 99.5% during the first quarter. Cullen Frost Bankers Inc. now owns 6,291 shares of the company’s stock worth $65,000 after acquiring an additional 3,137 shares during the period. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Stock Up 1.2%

Shares of NYSE:HLN opened at $9.81 on Friday. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. Haleon PLC Sponsored ADR has a 52-week low of $8.86 and a 52-week high of $11.42. The stock’s fifty day simple moving average is $9.85 and its 200-day simple moving average is $10.21. The company has a market capitalization of $43.97 billion, a P/E ratio of 25.14, a P/E/G ratio of 2.86 and a beta of 0.23.

Haleon Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Thursday, September 18th. Stockholders of record on Friday, August 15th will be given a $0.0555 dividend. This is an increase from Haleon’s previous semi-annual dividend of $0.05. This represents a dividend yield of 190.0%. The ex-dividend date is Friday, August 15th. Haleon’s dividend payout ratio (DPR) is currently 28.21%.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on HLN. Barclays reaffirmed an “overweight” rating on shares of Haleon in a report on Tuesday, May 6th. Morgan Stanley raised Haleon from an “equal weight” rating to an “overweight” rating and set a $11.25 price objective on the stock in a report on Friday, May 9th. Wall Street Zen lowered Haleon from a “buy” rating to a “hold” rating in a report on Saturday, July 12th. BNP Paribas raised Haleon to a “strong-buy” rating in a report on Tuesday, May 27th. Finally, BNP Paribas Exane raised Haleon from a “neutral” rating to an “outperform” rating and set a $13.40 price objective on the stock in a report on Tuesday, May 27th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $12.33.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.